Journals / Journal of Contemporary Medicine / 2024 / Cilt: 14 Sayı: 2

A determination of the quality of life of patients with vitiligo using the dermatological life quality index

Vitiligolu Hastalarda Dermatolojik Yaşam Kalite İndeksi Uygulanarak Yaşam Kalitesinin Etkilenme Derecesinin Belirtilmesi

Pages
83–87
Publication Date
2024-03-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The vitiligo and control groups’ mean DLQI scores were 5.5 ± 5.0 and 1.4 ± 1.3, respectively, the difference being statistically significant (p<0.05) Conclusion: The findings of this study show that the quality of life of the patients with vitiligo was significantly impaired compared to the control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Vitiligo is a severe skin disease that significantly affects individuals’ quality of life due to striking color changes in external appearance, and one that causes the majority of patients to feel stigmatized.
📊
Key Findings & Data:Results: Fifty patients with vitiligo and 50 healthy individuals were enrolled.
💡
Conclusion & Impact:The vitiligo and control groups’ mean DLQI scores were 5.5 ± 5.0 and 1.4 ± 1.3, respectively, the difference being statistically significant (p<0.05) Conclusion: The findings of this study show that the quality of life of the patients with vitiligo was significantly impaired compared to the control group.
🔬Design:Text.Serial.Journal
📍Scope:Comprehensive Sample
⚙️Variables:Vitiligo · Yaşam kalitesi · Psikoloji

Abstract

Background/aims: Vitiligo is a severe skin disease that significantly affects individuals’ quality of life due to striking color changes in external appearance, and one that causes the majority of patients to feel stigmatized. This study was conducted to determine the effects of vitiligo on patients’ psychological and social lives and to elucidate how they perceive the disease. Methods: The research was conducted as an epidemiological study. The Dermatological Life Quality Index (DLQI) was applied to patients with vitiligo presenting to our clinic and to a control group. Results: Fifty patients with vitiligo and 50 healthy individuals were enrolled. The vitiligo group consisted of 26 (52%) women and 24 (48%) men, and the healthy control group of 24 (48%) women and 26 (52%) men. The patients’ mean age was 37.2 ± 13.1 years, and that of the healthy controls 34.7 ± 9.2 years. (p=0.2). No significant age or sex differences were observed between the patient and control groups (p=0.2 and p<0.05, respectively). The mean duration of the disease was 83.9 ± 72.9 months. The most common vitiligo subtype was focal vitiligo, at 52%. The vitiligo and control groups’ mean DLQI scores were 5.5 ± 5.0 and 1.4 ± 1.3, respectively, the difference being statistically significant (p<0.05) Conclusion: The findings of this study show that the quality of life of the patients with vitiligo was significantly impaired compared to the control group.

Özet

Amaç: Vitiligo, dış görünümde göze çarpan renk değişiklikleri nedeniyle kişinin yaşam kalitesini önemli ölçüde etkileyen ve çoğu hastanın kendisini damgalanmış hissetmesine yol açan ciddi bir cilt hastalığıdır. Bu çalışmada vitiligonun hastaların psikolojik ve sosyal yaşantılarına etkilerinin saptanması ve hastaların hastalığı nasıl algıladıklarının anlaşılması amaçlanmaktadır. Gereç ve Yöntem: Çalışmamız epidemiyolojik bir çalışma olarak tasarlanmıştır. Polikiliniğimize başvuran vitiligolu hastalara ve kontrol gruplarına dermatolojik yaşam kalitesi indeksi uygulandı. Bulgular: Çalışmamıza 50 vitiligo hastası ve 50 sağlıklı kontrol grubu dahil edildi. Vitiligo hastalarının 26’sı (%52) kadın, 24’ü (%48) erkek’di. Sağlıklı kontrol grubunun 24’ü (%48) kadın, 26’sı (%52) erkek’di. Hastalarımızın yaş ortalamaları ve standart sapmaları 37.2 ± 13.1, sağlıklı kontrol grubunun yaş ortalamaları ve standart sapmaları 34.7 ± 9.2’di. Hastalarımız ve kontrol grubunun yaş ortalamaları istatistiksel olarak uyumlu bulundu (p=0.2). Yaş ve cinsiyet açısından hasta ve kontrol grupları arasında istatistiksel olarak uyum vardı (p<0.05). Ortalama hastalık süresi ve standart sapması 83,9 ± 72,9 ay olarak tespit edildi. Vitiligo klinik tipi olarak en sık görülen alt tip %52 ile fokal vitililigo oldu. Vitiligo ve kontrol gruplarında ortalama DYKİ skoru ve standart sapmaları sırasıyla 5.5 ± 5.0 ve 1.4 ± 1,3 olarak tespit edildi. Hasta grubumuzla sağlıklı kontrol grubu arasında istatistiksel olarak anlamlı bir fark bulundu. (p<0.05) Sonuç: Bizim çalışmamızdaki bulgular vitiligolu hastalarda yaşam kalitesinin kontrol grubuna göre önemli düzeyde bozulduğunu göstermiştir.

🔖

Cite This Article

Pala, E., Atasoy, M. (2024). A determination of the quality of life of patients with vitiligo using the dermatological life quality index. Journal of Contemporary Medicine, Cilt: 14 Sayı: 2, 83–87. https://doi.org/10.16899/jcm.1431049

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021
  2. 48(3):252-70 2. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012
  3. 51(10):1206-12 3. Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. Br J Dermatol. 2012
  4. 167(3):490-95 4. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020
  5. 48 5. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011
  6. 10(12):762-765 6. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000
  7. 39(11):801-6 7. Acıöz E, Gökdemir G, Köşlü A, Dermatolojide yaşam kalitesi. Turk Arch Dermatol Venereol 2003
  8. 16–23 8. Finlay AY, Khan GK. Dermatology life quality index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994
  9. 210–216 9. Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers. 2015
  10. 15011 10. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018
  11. 178(4):863-78 11. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011
  12. 65(3):473-91 12. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012
  13. 51(10):1206-1212. 13. Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: a study of 182 patients. Int J Dermatol. 2005
  14. 44(3):193-96 14. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol. 2003
  15. 20(3):207-10 15. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003
  16. 148(2):373-74 16. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol. 2004
  17. 8 17. Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vi